Nelarabine for Relapsed and Refractory T-ALL/T-LBL
While Nelarabine targets T-cells, it can also impact the immune system as a whole. This blog explores the balance between effectively treating T-ALL and T-LBL and managing the potential risks to the patient’s immune function. It also highlights the role of healthcare systems in facilitating access to essential cancer treatments.